Sexually transmitted disease surveillance 2001 supplement : Gonococcal Isolate Surveillance Project (GISP) annual report, 2001
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Sexually transmitted disease surveillance 2001 supplement : Gonococcal Isolate Surveillance Project (GISP) annual report, 2001

Filetype[PDF-7.49 MB]


Select the Download button to view the document
This document is over 5mb in size and cannot be previewed
  • English

  • Details:

    • Alternative Title:
      Gonococcal Isolate Surveillance Project (GISP) annual report, 2001;GISP 2001 surveillance supplement;
    • Personal Author:
    • Description:
      "With 361,705 gonorrhea cases reported in 2001, gonorrhea is the second most frequently reported communicable disease in the United States. Gonorrhea rates in the United States declined 73.8% during 1975-1997. However, in 1998, the reported rate of gonococcal infections in the United States (131.9 cases per 100,000 persons) increased by 7.8% compared with the 1997 rate (122.4 cases per 100,000 persons). In 2001, the gonorrhea rate was 128.5 cases per 100,000 population which represented little change from 1998. Gonorrhea rates remain high in the southeastern states, among minorities, and among adolescents of all racial and ethnic groups. The health impact of gonorrhea is largely related to its role as a major cause of pelvic inflammatory disease, which frequently leads to infertility or ectopic pregnancy. In addition, data suggest that gonorrhea facilitates HIV transmission. The treatment and control of gonorrhea has been complicated by the ability of Neisseria gonorrhoeae to develop resistance to antimicrobial agents. The appearance of penicillinase-producing N. gonorrhoeae (PPNG) and chromosomally mediated penicillin- and tetracycline-resistant N. gonorrhoeae (CMRNG) in the 1970s eventually led to the abandonment of these drugs as therapies for gonorrhea. The current CDC recommended primary therapies for gonorrhea are two broad-spectrum cephalosporins (ceftriaxone and cefixime), and three fluoroquinolones (ciprofloxacin, ofloxacin, and levofloxacin). However, since the 1990s, fluoroquinolone-resistant N. gonorrhoeae (QRNG) have been reported from many parts of the world, including the United States. The increased prevalence of QRNG in Asia (where prevalence in several countries exceeds 40%), the Pacific Islands, Hawaii, and, most recently, California, prompted CDC to recommend that fluroquinolones not be used to treat patients with gonorrhea acquired in these areas with high QRNG prevalence." -- p. 1.
    • Content Notes:
      Division of STD Prevention, prepared by Susan A. Wang, Alesia B. Harvey, Susan M. Conner, LuEtta Schneider and Hillard S. Weinstock.

      "October 2002."

      Also available via the World Wide Web.

      Includes bibliographical references (p. 11-13).

    • Document Type:
    • Place as Subject:
    • Main Document Checksum:
    • File Type:

    Supporting Files

    • No Additional Files

    More +

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov